周日夜盘交易中，Tonix Pharmaceuticals Holding Co（股票代码：TNXP）股价大幅上涨18.79%，引发市场广泛关注。这一显著涨幅主要源于该公司重大利好消息的公布。
据悉，美国食品和药物管理局（FDA）已批准Tonix制药用于治疗纤维肌痛（fibromyalgia）相关疼痛的新药。这款名为Tonmya的非阿片类药物是15年来首个获批用于纤维肌痛治疗的新药，为患者提供了新的治疗选择。Tonmya是一种专为睡前服用设计的药片，旨在改善睡眠质量并缓解慢性疼痛，这对纤维肌痛患者来说具有重要意义。
市场分析人士对Tonmya的前景持积极态度。扎克斯小盘股研究公司（Zacks Small-Cap Research）分析师戴维·鲍茨（David Bautz）预计，该药在美国的峰值年销售额可能在7到8年后达到8亿美元。考虑到目前纤维肌痛治疗市场存在巨大缺口，Tonix制药此次获批无疑为公司开辟了广阔的市场空间，这也解释了投资者对公司股票的热烈追捧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.